3M (MMM) Q1 2025 earnings summary

Executive summary

• Q1 2025 adjusted EPS was $1.88, up 10% year-over-year, with organic sales growth of 1.5% and adjusted operating margin up 220 basis points to 23.5%, driven by productivity and cost controls.

• GAAP EPS from continuing operations was $2.04, up 61% year-over-year, with net sales of $6.0B (down 1.0% YoY); adjusted sales were $5.8B, up 0.8% YoY.

• Free cash flow was $0.5B, with $1.7B returned to shareholders, including $1.3B in share repurchases and a 4% dividend increase.

• 62 new products were launched in Q1, a 60% increase year-over-year, with a robust pipeline targeting 215 launches in 2025.

• Completed Solventum (Health Care) spin-off in April 2024; 3M retains a 19.9% stake valued at $2.6B.

Financial highlights

• Adjusted sales were $5.8B, with organic growth of 1.5% year-over-year; adjusted operating margin was 23.5%, up 220 bps.

• Adjusted EPS was $1.88, up $0.17 or 10% year-over-year; GAAP EPS was $2.04, up 61% year-over-year.

• Free cash flow was $0.5B, with a 48% conversion rate; $1.7B returned to shareholders, including $1.3B in share repurchases.

• Board authorized a $7.5B share repurchase program, with 2025 repurchases expected to reach $2B.

• Net income from continuing operations was $1.12B, up from $705M year-over-year.

Outlook and guidance

• 2025 adjusted EPS guidance is $7.60–$7.90, with tariff sensitivity of $(0.20) to $(0.40) per share.

• Organic growth is expected at the lower end of the 2%-3% range due to a softer macro outlook.

• PFAS manufacturing exit expected by end of 2025; ongoing restructuring actions may continue.

• Free cash flow conversion expected to be approximately 100% for the year.

• No GAAP EPS guidance provided due to unpredictability of special items.